In a study using multiple myeloma cell lines, it was reported that treatment with pomalidomide (IMID®), an immunomodulatory FDA-approved drug for the treatment of multiple myeloma, increased nuclear mTOR and p-mTOR expression levels in the nucleus with a concomitant decrease of the cytoplasmic fractions (47). Here, MTOR is linked to plasma cell myeloma.